FCGR2A and neoplasm: For example, unlike conventional anti-CTLA-4 inhibitors, such as ipilimumab, the novel CTLA-4 inhibitor botensilimab (AGEN-1181) has been designed with an Fc-engineered IgG1 antibody, which has been shown to enhance Fc gamma receptor (FcγR)-dependent interactions, thus promoting superior anti-tumor activity.